Ankylosing Spondylitis Market
- 2026 年市場規模
- USD 7.28 Bn
- 2033 年預估規模
- USD 11.40 Bn
- 年複合成長率 CAGR
- 6.51%
以上數字由 Coherent Market Insights 於本報告中提出，量子訊息原樣引用。
授權報價
| Single User Price | $4,500 USD |
| Enterprise License | $10,000 USD |
完整報告名稱與涵蓋範圍
Ankylosing Spondylitis Market, By Drug Type (Nonsteroidal anti-inflammatory drugs (NSAIDs), Disease-modifying anti-rheumatic drugs (DMARDs), TNF Inhibitors, Corticosteroids, Others), By Route of Administration (Oral, Parenteral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)
報告摘要
Ankylosing Spondylitis Market is estimated to be valued at USD 7.28 Bn in 2026 and is expected to reach USD 11.40 Bn by 2033, growing at a CAGR of 6.51% from 2026 to 2033. The market is projected to witness steady growth owing to the rising prevalence of ankylosing spondylitis, increasing adoption of biologic therapies, expanding availability of biosimilars, and growing awareness regarding early diagnosis and disease management.
Ankylosing spondylitis (AS) is a chronic inflammatory autoimmune disorder that primarily affects the spine and sacroiliac joints, leading to pain, stiffness, and progressive loss of mobility. The disease can also affect peripheral joints and extra-articular organs, thereby significantly impacting quality of life. Growing awareness among healthcare professionals and patients, coupled with advancements in imaging technologies and biomarker-based diagnostics, is contributing to earlier diagnosis and improved treatment outcomes.
The market growth is further supported by increasing use of targeted biologic therapies, including tumor necrosis factor (TNF) inhibitors and interleukin-17 (IL-17) inhibitors, which have transformed the treatment landscape. Regulatory approvals of biosimilars and ongoing research in precision medicine are improving treatment accessibility and expanding therapeutic options. Organizations such as the Assessment of SpondyloArthritis International Society (ASAS), the American College of Rheumatology (ACR), and the European League Against Rheumatism (EULAR) continue to strengthen disease management guidelines, supporting wider adoption of advanced therapies.
Market Dynamics
The Ankylosing Spondylitis Market is driven by a combination of epidemiological, technological, and therapeutic factors.
One of the primary growth drivers is the increasing prevalence of ankylosing spondylitis and axial spondyloarthritis worldwide. Growing disease awareness and the availability of MRI-based diagnostic tools and HLA-B27 genetic testing are improving diagnosis rates and enabling early treatment intervention. Early diagnosis helps prevent structural damage and enhances long-term clinical outcomes, thereby driving demand for effective therapies.
Another major growth factor is the expanding use of biologics and targeted therapies. TNF inhibitors have become the standard treatment for moderate-to-severe disease, while IL-17 inhibitors have emerged as next-generation biologics offering therapeutic benefits for patients who do not adequately respond to anti-TNF agents. The rapid penetration of biosimilars across developed and emerging markets is lowering treatment costs and improving patient accessibility.
Technological innovations such as AI-assisted imaging analysis, digital biomarkers, electronic health records, wearable monitoring devices, and patient-reported outcome platforms are further enhancing disease monitoring and personalized care. These advancements are supporting better disease management and improving patient adherence to treatment.
However, the market faces challenges including high costs associated with biologic therapies, delayed diagnosis due to symptom overlap with other musculoskeletal disorders, and limited access to advanced treatments in low- and middle-income countries. Despite these restraints, ongoing investments in precision medicine, biomarker research, and next-generation targeted therapies are expected to create significant growth opportunities throughout the forecast period.
Key Features of the Study
• This report provides in-depth analysis of the Ankylosing Spondylitis Market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2026–2033), considering 2025 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the Ankylosing Spondylitis Market based on the following parameters – company highlights, service portfolio, key developments, financial performance, and strategies
• Key companies covered as a part of this study include Amgen Inc., AbbVie Inc., Pfizer Inc., Novartis AG, Bristol-Myers Squibb Company, CELGENE CORPORATION, Eli Lilly and Company, Cipla Inc., Emcure Pharmaceuticals, Torrent Pharmaceuticals Ltd., UCB S.A., Suzhou Zelgen Biopharmaceuticals Co., Ltd., HENGRUI USA, and Johnson & Johnson Services, Inc.
• Insights from this report would allow marketers and management authorities to make informed decisions regarding future service innovations, market expansion, and strategic partnerships
• The Ankylosing Spondylitis Market report caters to various stakeholders including investors, service providers, pharmaceutical companies, regulatory bodies, and financial analysts
• Stakeholders would benefit from structured analytical frameworks and strategy matrices used in evaluating the Ankylosing Spondylitis Market.
Market Segmentation
• By Drug Type (Revenue, USD Bn, 2021-2033)
o Nonsteroidal anti-inflammatory drugs (NSAIDs)
o Disease-modifying anti-rheumatic drugs (DMARDs)
o TNF Inhibitors
o Corticosteroids
o Others
• By Route of Administration (Revenue, USD Bn, 2021-2033)
o Oral
o Parenteral
• By Distribution Channel (Revenue, USD Bn, 2021-2033)
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
• By Region (Revenue, USD Bn, 2021-2033)
o North America
U.S.
Canada
o Latin America
Brazil
Mexico
Argentina
Rest of Latin America
o Europe
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
o Asia Pacific
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
o Middle East
GCC
Israel
Rest of Middle East
o Africa
South Africa
Central Africa
North Africa
• Key Players
o Amgen Inc.
o AbbVie Inc.
o Pfizer Inc.
o Novartis AG
o Bristol-Myers Squibb Company
o CELGENE CORPORATION
o Eli Lilly and Company
o Cipla Inc.
o Emcure Pharmaceuticals
o Torrent Pharmaceuticals Ltd.
o UCB S.A.
o Suzhou Zelgen Biopharmaceuticals Co., Ltd.
o HENGRUI USA
o Johnson & Johnson Services, Inc.
目錄 Table of Contents
Table of Contents
1. Research Objectives and Assumptions
o Research Objectives
o Assumptions
o Abbreviations
2. Market Purview
o Report Description
Market Definition and Scope
o Executive Summary
Market Snapshot, By Drug Type
Market Snapshot, By Route of Administration
Market Snapshot, By Distribution Channel
Market Snapshot, By Region
o Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
o Market Dynamics
Drivers
Restraints
Market Opportunities
o Impact Analysis
o Market Trends
o Key Developments
o Product Approval
o Collaboration/Merge/Acquisition
o Regulatory Landscape
o PEST Analysis
o Porter’s Five Forces Analysis
o Epidemiology
o Robust Pipeline Analysis
4. Ankylosing Spondylitis Market, By Drug Type, 2021 – 2033, (USD Billion)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022– 2033
Segment Trends
o Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
o Disease-modifying Anti-rheumatic Drugs (DMARDs)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
o TNF Inhibitors
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
o Corticosteroids
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
o Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
5. Ankylosing Spondylitis Market, By Route of Administration, 2021 – 2033, (USD Billion)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022– 2033
Segment Trends
o Oral
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
o Parenteral
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
6. Ankylosing Spondylitis Market, By Distribution Channel, 2021 – 2033, (USD Billion)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022– 2033
Segment Trends
o Hospital Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
o Retail Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
o Online Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
7. Ankylosing Spondylitis Market, By Region, 2021 – 2033, (USD Billion)
o Introduction
Market Share Analysis, By Region, 2026 and 2033 (%)
Y-o-Y Growth Analysis, For Regions, 2022–2033
Regional Trends
o North America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Billion)
o U.S.
o Canada
o Latin America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Billion)
o Brazil
o Mexico
o Argentina
o Rest of Latin America
o Europe
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Billion)
o U.K.
o Germany
o Italy
o France
o Spain
o Russia
o Rest of Europe
o Asia Pacific
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Billion)
o China
o India
o Japan
o ASEAN
o Australia
o South Korea
o Rest of Asia Pacific
o Middle East
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Billion)
o GCC
o Israel
o Rest of Middle East
o Africa
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 – 2033, (USD Billion)
o North Africa
o Central Africa
o South Africa
8. Competitive Landscape
o Heat Map Analysis
o Market Share Analysis
o Company Profile
Amgen Inc.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
AbbVie Inc.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Pfizer Inc.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Novartis AG
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Bristol-Myers Squibb Company
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
CELGENE CORPORATION
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Eli Lilly and Company
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Cipla Inc.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Emcure Pharmaceuticals
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Torrent Pharmaceuticals Ltd.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
UCB S.A.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Suzhou Zelgen Biopharmaceuticals Co., Ltd.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
HENGRUI USA
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Johnson & Johnson Services, Inc.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
o Analyst Views
9. Section
o References
o Research Methodology
o About Us
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們